"Complement Factor H" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
| Descriptor ID |
D017242
|
| MeSH Number(s) |
D12.776.124.486.274.920.325.200 D12.776.124.790.223.200 D12.776.377.715.182.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Complement Factor H".
Below are MeSH descriptors whose meaning is more specific than "Complement Factor H".
This graph shows the total number of publications written about "Complement Factor H" by people in this website by year, and whether "Complement Factor H" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement Factor H" by people in Profiles.
-
Heat-inactivated Factor B inhibits alternative pathway fluid-phase activation and convertase formation on endothelial cell-secreted ultra-large von Willebrand factor strings. Sci Rep. 2023 04 08; 13(1):5764.
-
CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance. Infect Immun. 2022 07 21; 90(7):e0006222.
-
Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring. Pediatr Nephrol. 2021 06; 36(6):1365-1375.
-
The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease. Infect Immun. 2020 04 20; 88(5).
-
Correlating Conformational Dynamics with the Von Willebrand Factor Reductase Activity of Factor H Using Single Molecule Force Measurements. J Phys Chem B. 2018 11 29; 122(47):10653-10658.
-
Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology. 2018 03; 125(3):391-397.
-
Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies. PLoS One. 2015; 10(3):e0121994.
-
HIF1A as a major vascular endothelial growth factor regulator: do its polymorphisms have an association with age-related macular degeneration? Clin Exp Ophthalmol. 2015 Jan-Feb; 43(1):47-53.
-
Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost. 2014 Jul; 40(5):544-50.
-
Human complement factor H is a reductase for large soluble von Willebrand factor multimers--brief report. Arterioscler Thromb Vasc Biol. 2013 Nov; 33(11):2524-8.